JP2023538065A5 - - Google Patents

Info

Publication number
JP2023538065A5
JP2023538065A5 JP2023511903A JP2023511903A JP2023538065A5 JP 2023538065 A5 JP2023538065 A5 JP 2023538065A5 JP 2023511903 A JP2023511903 A JP 2023511903A JP 2023511903 A JP2023511903 A JP 2023511903A JP 2023538065 A5 JP2023538065 A5 JP 2023538065A5
Authority
JP
Japan
Prior art keywords
compound
subject
administering
cholesterol
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023511903A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538065A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/046589 external-priority patent/WO2022040369A1/en
Publication of JP2023538065A publication Critical patent/JP2023538065A/ja
Publication of JP2023538065A5 publication Critical patent/JP2023538065A5/ja
Pending legal-status Critical Current

Links

JP2023511903A 2020-08-19 2021-08-19 多発性硬化症の寛解を処置する方法 Pending JP2023538065A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063067727P 2020-08-19 2020-08-19
US63/067,727 2020-08-19
PCT/US2021/046589 WO2022040369A1 (en) 2020-08-19 2021-08-19 Methods for treating remitting multiple sclerosis

Publications (2)

Publication Number Publication Date
JP2023538065A JP2023538065A (ja) 2023-09-06
JP2023538065A5 true JP2023538065A5 (cg-RX-API-DMAC7.html) 2024-08-23

Family

ID=77693630

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023511903A Pending JP2023538065A (ja) 2020-08-19 2021-08-19 多発性硬化症の寛解を処置する方法

Country Status (6)

Country Link
US (1) US20230390270A1 (cg-RX-API-DMAC7.html)
EP (1) EP4199927A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023538065A (cg-RX-API-DMAC7.html)
CN (1) CN116096421A (cg-RX-API-DMAC7.html)
TW (1) TW202227069A (cg-RX-API-DMAC7.html)
WO (1) WO2022040369A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12472171B2 (en) * 2020-08-19 2025-11-18 Biogen Ma Inc. Methods for treating hypercholesterolemia
WO2023154925A1 (en) * 2022-02-14 2023-08-17 Genetic Innovations, Inc. Medical spectroscopy and imaging analysis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA034451B1 (ru) * 2011-02-07 2020-02-10 Байоджен Ма Инк. Модуляторы s1p
JP6324380B2 (ja) * 2012-07-27 2018-05-16 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｓ１ｐ調節剤および／またはａｔｘ調節剤である化合物
CA2899322A1 (en) * 2013-01-29 2014-08-07 Biogen Ma Inc. S1p modulating agents

Similar Documents

Publication Publication Date Title
JP2004531468A5 (cg-RX-API-DMAC7.html)
JP2505944B2 (ja) （Ｓ）―α―フルオロメチル―ヒスチジン及びそのエステルを含有するぜん息治療用医薬組成物
JP2002540147A5 (cg-RX-API-DMAC7.html)
JP2009534384A (ja) オピオイドアンタゴニストによる炎症性および潰瘍性腸疾患の治療
EP4520394A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
JP2022533968A5 (cg-RX-API-DMAC7.html)
JP2023538065A5 (cg-RX-API-DMAC7.html)
JP2022500366A (ja) 肝疾患治療のための併用療法
JP2006513184A5 (cg-RX-API-DMAC7.html)
JP2024533423A5 (cg-RX-API-DMAC7.html)
JP2023527542A5 (cg-RX-API-DMAC7.html)
JP2021502392A5 (cg-RX-API-DMAC7.html)
CA2942021C (en) Osmolytes for treating allergic or viral respiratory diseases
JP2024517085A5 (cg-RX-API-DMAC7.html)
JP2023549849A5 (cg-RX-API-DMAC7.html)
JP2023510341A5 (ja) ナルブフィン治療可能障害を治療するために投与されるナルブフィン製剤
JP2023531675A5 (cg-RX-API-DMAC7.html)
Gerolami et al. Controlled trial of chenodeoxycholic therapy for radiolucent gallstones: a multicenter study
JP2009545546A (ja) リウマチ性疾患の遅延放出型グルココルチコイド治療
JP2024539476A5 (cg-RX-API-DMAC7.html)
JP2023538066A5 (cg-RX-API-DMAC7.html)
CA2385974A1 (en) Treating endometriosis or infertility or improving fertility
JP2024525897A5 (cg-RX-API-DMAC7.html)
RU98114080A (ru) Биологически активные этанамины бензотиазолона
CN119654168A (zh) 用于治疗自身免疫疾病的方法